The human cancer cell line ICC9 (ACC 1000) was established in the group of Prof. Nabeel Bardeesy at Massachusetts General Hospital, Center for Cancer Research, Cambridge, Boston. It is one of a total of 18 tumor cell lines generously provided to the DSMZ by Prof. Bardeesy for inclusion in our cell line collection. All 18 cell lines were recently derived from samples of biliary tract cancers (BTCs). These malignant tumors are very rare and often associated with a poor prognosis for patients. Therefore, there is an urgent need for robust in vitro models to support the development of new therapeutic approaches.
Prof. Bardeesy’s cell lines represent different subtypes of these tumors, and his research group has extensively characterized them genetically and molecularly. The data have recently been published in a comprehensive BTC cell line atlas in the prestigious journal Cancer Discovery. These cell lines thus constitute highly valuable new tumor models, which are now made available worldwide to researchers through the DSMZ catalogue.
The ICC9 cell line (ACC 1000), was established in 2016 from the primary tumor of a 38-year-old male patient diagnosed with intrahepatic cholangiocarcinoma (abbreviated as ICC). ICC9 is an adherently growing cell line exhibiting epithelial morphology. The cell nuclei and nucleoli are clearly visible under phase-contrast microscopy (see picture).
Background: DSMZ is one of the world’s leading biorepositories, providing authenticated cell lines for research. The addition of the 1,000th cell line highlights DSMZ's role in offering a comprehensive and diverse resource for researchers. These cell lines serve as essential models in cancer and infection research, drug screening, and other life sciences. DSMZ ensures the reliability and reproducibility of scientific work by offering high-quality, well-characterized cell lines with extensive accompanying data such as RNA sequencing, STR profiles (for identification), and more. This resource helps the scientific community select appropriate models, avoid misidentification, and supports advances in biomedical research
